{"transactions":[{"id":1478684,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-14T20:10:09.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.31,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073650","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024073650/ownership.xml","form_type":"4"}},{"id":1634122,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-20T22:27:03.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.52,"exercise_date":"2023-06-23","expiration_date":"2032-06-23","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001062993-24-003733","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000106299324003733/form4.xml","form_type":"4"}},{"id":1634121,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-20T22:27:03.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":19218,"price":4.76,"value":91477.68,"ownership":{"direct":true},"balance_after":17082,"source":{"system":"sec-edgar","filing":"0001062993-24-003733","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000106299324003733/form4.xml","form_type":"4"}},{"id":1634120,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-20T22:27:03.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":36300,"price":2.52,"value":91476.0,"ownership":{"direct":true},"balance_after":36300,"source":{"system":"sec-edgar","filing":"0001062993-24-003733","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000106299324003733/form4.xml","form_type":"4"}},{"id":1835442,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-06T01:50:13.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.11,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-031869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023031869/ownership.xml","form_type":"4"}},{"id":1845383,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T20:10:52.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date."}],"balance_after":36300,"derivative":{"exercise_price":2.4,"expiration_date":"2033-06-21","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001062993-23-013980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000106299323013980/form4.xml","form_type":"4"}},{"id":2221320,"issuer":{"id":9881,"kind":"organization","name":"LianBio"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T21:37:52.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date."}],"balance_after":36300,"derivative":{"exercise_price":2.52,"expiration_date":"2032-06-23","underlying":"Ordinary Shares","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001062993-22-015490","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831283/000106299322015490/form4.xml","form_type":"4"}},{"id":2225097,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-21T20:06:07.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":5.09,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-22-023337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924322023337/doc4.xml","form_type":"4"}},{"id":2690932,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-05-28T22:25:19.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":7.24,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-21-021189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924321021189/doc4.xml","form_type":"4"}},{"id":2871131,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":34951,"price":14.6,"value":510284.6,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14869915,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2871130,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":64730,"price":13.8,"value":893274.0,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14834964,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2871129,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-08","kind":"purchase","acquired":true,"shares":1771,"price":13.1,"value":23200.1,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14770234,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2871128,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-08","kind":"purchase","acquired":true,"shares":86671,"price":12.53,"value":1085987.63,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14768463,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2871127,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-08","kind":"purchase","acquired":true,"shares":34611,"price":11.38,"value":393873.18,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14681792,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2871126,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T19:56:00.000Z","date":"2021-02-05","kind":"purchase","acquired":true,"shares":27453,"price":11.14,"value":305826.42,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":14647181,"source":{"system":"sec-edgar","filing":"0001209191-21-009047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121009047/doc4.xml","form_type":"4"}},{"id":2873999,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-08T18:08:01.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":7486190,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PLSMF, 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PXVF and 1,770,600 shares of common stock issuable upon conversion of Series B preferred stock held by PXV. Perceptive Advisors serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7486190},"source":{"system":"sec-edgar","filing":"0001209191-21-008587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121008587/doc4.xml","form_type":"4"}},{"id":2873998,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-02-08T18:08:01.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":5883538,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PLSMF and 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5883538},"source":{"system":"sec-edgar","filing":"0001209191-21-008587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121008587/doc4.xml","form_type":"4"}},{"id":2873997,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-08T18:08:01.000Z","date":"2021-02-08","kind":"purchase","acquired":true,"shares":1250000,"price":16,"value":20000000.0,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":14619728,"source":{"system":"sec-edgar","filing":"0001209191-21-008587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121008587/doc4.xml","form_type":"4"}},{"id":2873996,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-08T18:08:01.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":13369728,"ownership":{"direct":false,"nature":"By funds"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consists of 5,799,564 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. (\"PLSMF\"), 5,799,564 shares of common stock held by Perceptive Xontogeny Venture Fund, LP (\"PXVF\"), and 1,770,600 shares of common stock held by PX Venture (A), LLC (\"PXV\"). Perceptive Advisors, LLC (\"Perceptive Advisors\") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":13369728,"source":{"system":"sec-edgar","filing":"0001209191-21-008587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678736/000120919121008587/doc4.xml","form_type":"4"}},{"id":3165228,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-05-01T22:38:02.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020."}],"balance_after":14500,"derivative":{"exercise_price":16,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0000899243-20-011751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924320011751/doc4.xml","form_type":"4"}},{"id":4134444,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President, CFO"}}],"security":"Stock Appreciation Right","published_at":"2017-12-12T16:08:09.000Z","date":"2017-12-08","kind":"grant","acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant."}],"balance_after":205000,"derivative":{"exercise_price":3.64,"expiration_date":"2027-12-08","underlying":"Common Stock, par value $0.001","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001593968-17-001351","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000159396817001351/primary_01.xml","form_type":"4"}},{"id":4518405,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2016-12-16T20:22:23.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":350000,"price":4.66,"value":1631000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes vested and exercisable in three equal annual installments over 3 years from December 15, 2016, the date of grant, with vesting to accelerate if employment ends for any reason other than a termination for Cause, as defined in the relevant employment agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."}],"balance_after":350000,"derivative":{"exercise_price":4.66,"expiration_date":"2026-12-15","underlying":"Common Stock, par value $0.001","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001593968-16-001349","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000159396816001349/primary_01.xml","form_type":"4"}},{"id":4557194,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common stock, par value $0.001","published_at":"2016-11-14T08:41:46.000Z","date":"2016-11-11","kind":"purchase","acquired":true,"shares":1000,"price":5.43,"value":5430.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001557142-16-000040","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000155714216000040/primary_doc.xml","form_type":"4"}},{"id":4557193,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common stock, par value $0.001","published_at":"2016-11-14T08:41:46.000Z","date":"2016-11-11","kind":"purchase","acquired":true,"shares":1000,"price":5.95,"value":5950.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001557142-16-000040","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000155714216000040/primary_doc.xml","form_type":"4"}},{"id":4557192,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common stock, par value $0.001","published_at":"2016-11-14T08:41:46.000Z","date":"2016-11-11","kind":"purchase","acquired":true,"shares":1000,"price":5.91,"value":5910.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001557142-16-000040","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000155714216000040/primary_doc.xml","form_type":"4"}},{"id":4557191,"issuer":{"id":133686,"kind":"organization","name":"Kadmon Holdings, Inc.","symbol":"KDMN"},"owners":[{"id":88627,"kind":"person","name":"Poukalov Konstantin","position":1,"cik":"0001678736","reported_name":"Poukalov Konstantin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common stock, par value $0.001","published_at":"2016-11-14T08:41:46.000Z","date":"2016-11-11","kind":"purchase","acquired":true,"shares":1000,"price":5.96,"value":5960.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001557142-16-000040","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557142/000155714216000040/primary_doc.xml","form_type":"4"}}]}